Artia Global Partners LP Invests $2.32 Million in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Artia Global Partners LP acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 102,900 shares of the company's stock, valued at approximately $2,315,000. Enliven Therapeutics comprises 0.8% of Artia Global Partners LP's investment portfolio, making the stock its 20th largest holding. Artia Global Partners LP owned approximately 0.21% of Enliven Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lord Abbett & CO. LLC raised its holdings in shares of Enliven Therapeutics by 20.3% during the 4th quarter. Lord Abbett & CO. LLC now owns 386,211 shares of the company's stock valued at $8,690,000 after buying an additional 65,156 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Enliven Therapeutics by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock worth $307,000 after acquiring an additional 1,980 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of Enliven Therapeutics by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock valued at $489,000 after purchasing an additional 1,285 shares during the last quarter. Finally, Barclays PLC raised its position in Enliven Therapeutics by 14.8% in the 4th quarter. Barclays PLC now owns 64,563 shares of the company's stock worth $1,453,000 after purchasing an additional 8,346 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Stock Performance

ELVN stock traded up $0.90 on Friday, reaching $20.75. The company's stock had a trading volume of 89,826 shares, compared to its average volume of 260,227. The firm has a market cap of $1.02 billion, a PE ratio of -10.92 and a beta of 1.03. The business has a fifty day simple moving average of $19.16 and a two-hundred day simple moving average of $22.47. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the sale, the chief operating officer now directly owns 329,977 shares of the company's stock, valued at $7,236,395.61. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samuel Kintz sold 12,500 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at $20,629,865.36. This represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,751 shares of company stock worth $1,331,288. Company insiders own 29.20% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.